
Ask a doctor about a prescription for PALMEUX 150 mg PROLONGED-RELEASE INJECTABLE SUSPENSION IN PRE-FILLED SYRINGE
Package Leaflet: Information for the User
Palmeux 25mg prolonged-release injectable suspension in a pre-filled EFG syringe
Palmeux 50mg prolonged-release injectable suspension in a pre-filled EFG syringe
Palmeux 75mg prolonged-release injectable suspension in a pre-filled EFG syringe
Palmeux 100mg prolonged-release injectable suspension in a pre-filled EFG syringe
Palmeux 150mg prolonged-release injectable suspension in a pre-filled EFG syringe
Paliperidone
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack
This medicine contains the active substance paliperidone, which belongs to a class of medicines called antipsychotics, and is used as maintenance treatment for symptoms of schizophrenia in adult patients stabilized with paliperidone or risperidone.
If you have shown a response to paliperidone or risperidone in the past and have mild or moderate symptoms, your doctor may start treatment with Palmeux without prior stabilization with paliperidone or risperidone.
Schizophrenia is a disorder with "positive" and "negative" symptoms. Positive means an excess of symptoms that are not normally present. For example, a person with schizophrenia may hear voices or see things that do not exist (called hallucinations), have false beliefs (called delusions), or have an abnormal distrust of others. Negative refers to the lack of behaviors or feelings that are normally present. For example, a person with schizophrenia may withdraw into themselves and not respond to any emotional stimulus or may have problems speaking in a clear and logical manner. People with this disorder may also feel depressed, anxious, guilty, or tense.
This medicine may help alleviate the symptoms of your illness and prevent them from coming back.
Do not use Palmeux:
Warnings and precautions
Talk to your doctor, pharmacist, or nurse before starting to use Palmeux.
This medicine has not been studied in elderly patients with dementia. However, elderly patients with dementia who are being treated with other similar medicines may have an increased risk of stroke or death (see section 4, possible side effects).
All medicines can cause side effects, and some of the side effects of this medicine may worsen the symptoms of other conditions. For this reason, it is important that you discuss with your doctor any of the following conditions, which may worsen during treatment with this medicine:
If you have any of these conditions, please consult your doctor, as it may be necessary to adjust your dose or keep you under observation for a while.
Because it has been rarely observed in patients treated with this medicine that there is a dangerously low number of a type of white blood cells necessary to fight infections in the blood, your doctor may check your white blood cell count.
Even if you have previously tolerated oral paliperidone or risperidone, rare allergic reactions may occur after receiving Palmeux injections. Seek medical help immediately if you experience a skin rash, throat swelling, itching, or breathing problems, as these may be signs of a severe allergic reaction.
This medicine may cause you to gain weight. Significant weight gain can negatively affect your health. Your doctor will regularly monitor your weight.
In patients treated with this medicine, diabetes mellitus or worsening of pre-existing diabetes mellitus has been observed, and your doctor should check for signs of high blood sugar. In patients with pre-existing diabetes mellitus, blood sugar should be regularly monitored.
Since this medicine can reduce the urge to vomit, there is a possibility that it may mask the body's normal response to ingesting toxic substances or other conditions.
During eye surgery for cataracts, the pupil (the black circle in the center of the eye) may not increase in size as needed. Additionally, the iris (the colored part of the eye) may become flaccid during surgery, which can cause eye damage. If you are planning to have eye surgery, make sure to inform your ophthalmologist that you are using this medicine.
Children and adolescents
Do not use this medicine in children under 18 years of age.
Other medicines and Palmeux
Tell your doctor if you are using, have recently used, or might use any other medicines.
Taking this medicine with carbamazepine (an antiepileptic and mood stabilizer) may require a change in your dose of this medicine.
Since this medicine acts mainly on the brain, interaction with other medicines that also act on it may cause an exaggeration of side effects, such as drowsiness or other effects on the brain, such as other psychiatric medicines, opioids, antihistamines, and sleeping medicines.
Since this medicine can lower blood pressure, you should be careful if you use this medicine with other medicines that also lower blood pressure.
This medicine may reduce the effect of medicines for Parkinson's disease and restless legs syndrome (e.g., levodopa).
This medicine may cause an abnormality in the electrocardiogram (ECG) that shows that it is necessary to have a prolonged period for an electrical impulse to travel through a certain part of the heart (known as "prolongation of the QT interval"). Other medicines that have this effect include some medicines used to treat heart rhythm or to treat infections, in addition to other antipsychotics.
If you are prone to seizures, this medicine may increase your chances of experiencing them. Other medicines that have this effect include some medicines used to treat depression or to treat infections, in addition to other antipsychotics.
Palmeux should be used with caution with medicines that increase the activity of the central nervous system (psychostimulants such as methylphenidate).
Palmeux with alcohol
Alcohol should be avoided.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine. You should not use this medicine during pregnancy unless you have discussed it with your doctor. The following symptoms may occur in newborn babies of mothers who have been treated with paliperidone in the last trimester of pregnancy (the last three months of pregnancy): tremor, stiffness and/or muscle weakness, drowsiness, agitation, breathing problems, and difficulty feeding. If your baby develops any of these symptoms, you should contact your doctor.
This medicine may pass from mother to child through breast milk and may harm the baby. Therefore, you should not breastfeed while using this medicine.
Driving and using machines
During treatment with this medicine, dizziness, extreme fatigue, and vision problems (see section 4) may occur. This should be taken into account when maximum alertness is required, e.g., when driving or operating machines.
Palmeux contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per dose; i.e., it is essentially "sodium-free".
.
Your doctor or another healthcare professional will administer this medicine to you. Your doctor will tell you when you should receive the next injection. It is important that you do not miss any of your scheduled doses. If you cannot attend your appointment with your doctor, make sure to call them immediately to schedule another appointment as soon as possible.
You will receive the first injection (150 mg) and the second injection (100 mg) of this medicine in the upper arm approximately one week apart. From then on, you will receive an injection (of 25 mg to 150 mg) in the upper arm or buttocks once a month.
If your doctor is switching you from risperidone long-acting injection to this medicine, you will receive the first injection of this medicine (of 25 mg to 150 mg) in the upper arm or buttocks at the next scheduled injection. From then on, you will receive an injection (of 25 mg to 150 mg) in the upper arm or buttocks once a month.
Depending on your symptoms, your doctor may increase or decrease the amount of medicine you receive at a dose level at the time of the monthly scheduled injection.
Patient with kidney problems
Your doctor may adjust the dose of this medicine according to your kidney function. If you have mild kidney problems, your doctor may give you a lower dose. You should not use this medicine if you have moderate or severe kidney problems.
Elderly patients
Your doctor may reduce the dose of this medicine if your kidney function is decreased.
If you receive more Palmeux than you should
You will receive this medicine under medical supervision; it is, therefore, unlikely that you will receive an excessive dose.
Patient who have received an overdose of paliperidone may experience the following symptoms: drowsiness or sedation, rapid heartbeat, low blood pressure, abnormalities in the electrocardiogram (heart tracing), or slow or abnormal movements of the face, body, arms, or legs.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, telephone 91 562 04 20, indicating the medicine and the amount ingested.
If you stop using Palmeux
If you stop receiving your injections, the effects of the medicine will be lost. You should not stop using this medicine unless your doctor tells you to, as your symptoms may come back.
If you have any further questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Report immediately to your doctor if:
The following adverse effects may appear:
Very common adverse effects: may affect more than 1 in 10 patients
Common adverse effects: may affect up to 1 in 10 patients
Uncommon adverse effects: may affect up to 1 in 100 patients
Rare adverse effects: may affect up to 1 in 1,000 patients
Frequency not known: cannot be estimated from the available data
dead skin cells at the injection site and ulcer at the injection site.
Reporting of adverse effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect that does not appear in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date that appears on the box and on the pre-filled syringe after CAD. The expiration date is the last day of the month indicated.
Do not store above 30°C.
Medicines should not be disposed of through wastewater or household waste. Deposit the containers and medicines you no longer need at the SIGRE point in the pharmacy. In case of doubt, ask your pharmacist how to dispose of the containers and medicines you no longer need. This way, you will help protect the environment.
Palmeux Composition
The active ingredient is paliperidone.
Each Palmeux 25 mg pre-filled syringe contains 25 mg of paliperidone (as paliperidone palmitate).
Each Palmeux 50 mg pre-filled syringe contains 50 mg of paliperidone (as paliperidone palmitate).
Each Palmeux 75 mg pre-filled syringe contains 75 mg of paliperidone (as paliperidone palmitate).
Each Palmeux 100 mg pre-filled syringe contains 100 mg of paliperidone (as paliperidone palmitate).
Each Palmeux 150 mg pre-filled syringe contains 150 mg of paliperidone (as paliperidone palmitate).
The other components are:
Polysorbate 20
Macrogol
Citric acid monohydrate
Sodium phosphate anhydrous
Sodium dihydrogen phosphate monohydrate
Sodium hydroxide (for pH adjustment)
Water for injectable preparations
Product Appearance and Container Contents
Palmeux is a white to off-white prolonged-release injectable suspension that comes in a pre-filled syringe.
Each pack contains 1 pre-filled syringe and 2 needles.
Marketing Authorisation Holder
Amdipharm Limited
3 Burlington Road
D04 RD68 Dublin 4,
Ireland
Manufacturer
Pharmathen S.A
Dervenakion 6,
Pallini Attiki, 15351,
Greece
Or
Pharmathen International S.A
Industrial Park Sapes,
Rodopi Prefecture, Block No 5,
Rodopi 69300,
Greece
Local Representative:
Advanz Pharma Spain S.L.U.
Paseo de la Castellana 135, 7th floor
28046 Madrid (Spain)
Tel: +34 900 834 889
Date of Last Revision of this Leaflet:September 2021.
Detailed and up-to-date information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
------------------------------------------------------------------------------------------------------------------------
This information is intended solely for healthcare professionals and should be read in conjunction with the complete prescribing information (Summary of Product Characteristics).
The injectable suspension is for single use. It should be visually examined for any foreign particles before administration. Do not use the product if the syringe is not visually free from foreign particles.
The pack contains a pre-filled syringe and two safety needles (one 22-gauge 1½-inch needle and one 23-gauge 1-inch needle) for intramuscular injection

Shake the syringe vigorously for at least 10 seconds to ensure a homogeneous suspension.The first initiation dose of Palmeux (150 mg) is administered on Day 1 in the DELTOID muscle using the needle for DELTOID injection. The second initiation dose of Palmeux (100 mg) is also administered in the DELTOID muscle one week later (Day 8) using the needle for DELTOID injection.
If the patient is being switched from prolonged-release injectable risperidone to Palmeux, the first Palmeux injection (dose range 25 mg to 150 mg) can be administered in the DELTOID muscle or GLUTEAL muscle using the appropriate needle for the injection site at the time of the next scheduled injection.
Subsequent monthly maintenance injections can be administered in either the DELTOID or GLUTEAL muscle using the appropriate needle for the injection site.
In the case of DELTOID injection, if the patient weighs <90 kg, use the 23-gauge 1-inch (25.4 mm x 0.64 mm) needle (needle with blue hub); if patient weighs ≥ 90 22-gauge 1½-inch (38.1 0.72 gray hub).< p>
In the case of GLUTEAL injection, use the 22-gauge 1½-inch (38.1 mm x 0.72 mm) needle (needle with gray hub).



8a

8b

8c

The average price of PALMEUX 150 mg PROLONGED-RELEASE INJECTABLE SUSPENSION IN PRE-FILLED SYRINGE in October, 2025 is around 262.27 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for PALMEUX 150 mg PROLONGED-RELEASE INJECTABLE SUSPENSION IN PRE-FILLED SYRINGE – subject to medical assessment and local rules.